Our group develops research directed to the most prevalent health problems in respiratory pathologies. We are an associated group in IMIBIC composed by several emerging researcher who dedicate their principal work to clinical care in HURS. The objectives of our researches are always oriented in achieving results that have applicability in clinical practice and influence the global management (diagnosis, therapy and monitoring) of the patient with respiratory pathology. We aim at establishing alliances with other groups nationwide and internationally, that carry out research based on omics of chronic respiratory diseases. On institutional level, we welcome new researchers in the group through which to establish alliances between other IMIBIC groups and to create synergies in the common areas of research. We want to consolidate our research in the screening for lung cancer as a more effective tool to reduce the mortality of this tumor. In addition, we are beginning with new research lines to implement platforms based on the new omics for the therapeutic control and prognosis of chronic inflammatory diseases of the respiratory system (COPD-asthma); and other to determine the effect of the inhalation of toxic particles (environmental contamination) in respiratory pathology.
Our group was a pioneer in demonstrating the usefulness of human sweat analysis in lung cancer. In addition we have collaborated in the investigation of the effect of intermittent hypoxemia with the IMIBIC group of 'Nutrigenomics, Metabolic Syndrome' in patients with vascular risk factors to determine the consequences of the effect of hypoxemia on the effect of the Mediterranean diet and the vascular risk.
Currently, we collaborate with Dr. Antonio Rodríguez Ariza (Coordinator of Oncover study, GC-06 New therapies in cancer) and Dr. Mª Dolores Luque de Castro (GC-21 Metabolomics. Identification of bioactive components) in the identification and quantification of useful compounds in the diagnosis of Lung cancer in the condensate of the exhaled air. In this same line, we also collaborated with the group of Dr. Mª Dolores Luque de Castro in the identification of clinical phenotypes through metabolomic studies in exhaled air condensate, and in the search for new markers in lung cancer in various biofluids.
We are carrying out two multicenter studies, one with the San Pedro Alcántara Hospital from Cáceres and others, in which we analyse the influence of suffering Sleep Apnea in the worsening of Kidney Disease, as well as the improvement of the CKD if these apneas are corrected with either AutoCPAP or other treatments. Another collaborative study we are involved in is with the Valme Hospital in Seville and others, in which we study the association of sleep apnea with impaired metabolism and prostate tumor prognosis.
Exhaled breath condensate (EBC) is one of the less employed biofluids when searching for clinical markers, despite its non-invasive sampling and the potential relationship between its composition and respiratory disease. Two studies using metabolomics are underway: i) We use EBC as clinical sample to develop a screening tool for lung cancer discrimination, and ii) perform untargeted analysis of EBC with a cohort of patients with lung cancer, risk factor individuals and control group of healthy individuals in order to identify compounds that contribute to discrimination between the different groups and a relevant role for lipids, such as monoacylglycerols and squalene. The results of these studies may support the ability of metabolomics for the study of lung. Within this line of study, we also explore whether proteomic analysis of exhaled breath condensate (EBC) may provide biomakers for non-invasive screening for the early detection of lung cancer.
Sweat has recently gained popularity as a potential tool for diagnostics and biomarker monitoring as it is a non-invasive bioﬂuid the composition of which could be modiﬁed by certain pathologies. We have compared different simple preparation protocols as well as different chromatographic modes for global metabolomics proﬁling analysis of sweat. Although sweat is scarcely used in metabolomics studies, its potential for discrimination of metabolic proﬁles correlated with different pathologies would make this bioﬂuid interesting to explore. Thus, we are interested in applying a method based on metabolite analysis of sweat to discriminate between patients with lung cancer vs smokers as control group
Bronchoalveolar lavage fluid (BALF) analysis can contribute to clinical practice with more sensitive biomarkers, thus complementing cytohistological studies in order to aid in the diagnosis, prognosis, and subtyping of lung cancer, as well as the monitoring of treatment response. Our studies in this area focus on candidate protein biomarkers for adenocarcinoma in BALF. The preliminary results are encouraging in terms of the number of identified and quantified proteins, demonstrating that the analysis of BALF proteins by a SWATH approach is a useful method for the discovery of potential biomarkers of pulmonary diseases.
- cell damage
- chronic respiratory disease
- respiratory therapies
- López-Sánchez LM, Jurado-Gámez B, Feu-Collado N, Valverde A, Cañas A, Fernández-Rueda JL, Aranda E, Rodríguez-Ariza A. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol. 2017 Oct 1;313(4):L664-L676. doi: 10.1152/ajplung.00119.2017.
- Ortea I, Rodríguez-Ariza A, Chicano-Gálvez E, Arenas Vacas MS, Jurado Gámez B. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J Proteomics. 2016 Apr 14;138:106-14. Q1
- Peralbo-Molina A, Calderón-Santiago M, Priego-Capote F, Jurado-Gámez B, Luque de Castro MD. Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate. Journal of Breath Research. 2016. 10(2):026002. FI=4.318; Q1
- Calderón-Santiago M, Priego-Capote F, Turck N, Robin X, Jurado-Gámez B, Sanchez JC, Luque de Castro MD. Human sweat metabolomics for lung cancer screening. Analytical and bioanalytical chemistry. 2015. 407(18):5381-92. FI=3.436; Q1